SMARCA2 and breast carcinoma: The dynamics of m6A methylation, particularly in transitioning to BrM in ER+ breast cancer, show global methyl gains and specific pathway alterations, implicating stem cell differentiation as a pivotal factor influenced by the altered epi-transcriptome [124].